北京赛升药业股份有限公司 证券代码：300485 证券简称：赛升药业 公告编号：2025-044 第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 审议通过《关于公司拟出售部分交易性金融资产的议案》 为进一步整合公司资产结构，提高经营效率及资金使用效率，同意公司管理 层在严格遵守相关法律法规的条件下，根据证券市场情况及公司经营状况，择机 出售公司持有的北京绿竹生物技术股份有限公司及北京康乐卫士生物技术股份 有限公司股票。授权期限为自董事会审议通过之日起12个月内。 具 体 内 容 详 见 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）。 表决结果：赞成 8 票、反对 0 票、弃权 0 票、回避 0 票。 三、备查文件 第五届董事会第十一次会议决议 特此公告。 北京赛升药业股份有限公司 董 事 会 2025 年 10 月 31 日 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第十一次会 议于2025年10月3 ...

Group 1 - Hu Silicon Industry plans to reduce its shareholding by up to 2%, amounting to a maximum of 54.94 million shares, during the period from November 17, 2025, to February 16, 2026 [1] - Lixin Micro intends to reduce its shareholding by up to 3%, totaling a maximum of 4.01 million shares, from November 14, 2025, to February 13, 2026 [2] - Dual Good Energy signed a contract worth $119 million with Ust-Kamenogorsk CHP LLP in Kazakhstan, representing 6.50% of its audited revenue for 2024 [3] Group 2 - Dual Good Energy plans to raise up to 1.29 billion yuan through a private placement for projects including zero-carbon intelligent manufacturing [5] - Top Cloud Agriculture's shareholders plan to reduce their holdings by up to 3.3%, with specific reductions of 1% and 2.30% from different parties [7] - Hwa Woo Co. reported a 70.84% increase in net profit for the first three quarters, with revenue reaching 994 million yuan, a 16.55% increase year-on-year [8] Group 3 - Chongde Technology's net profit increased by 19.68% in the first three quarters, with revenue of 445 million yuan, a 20.25% increase [10] - New Meixing reported a 191.95% increase in net profit for the first three quarters, with revenue of 870 million yuan, a 15.88% increase [11] - Sanxia New Materials reported a net loss of 59.85 million yuan in the first three quarters, with revenue declining by 27.29% [13] Group 4 - Wanma Co. achieved a 61.57% increase in net profit for the first three quarters, with revenue of 14.11 billion yuan, an 8.36% increase [14] - Chengdu Road and Bridge announced that 7% of its shares, totaling 52.997 million shares, will be auctioned [15] - BGI Genomics plans to jointly apply for a national science project with a total budget of 120 million yuan [17] Group 5 - Qiangbang New Materials plans to reduce its shareholding by up to 1.49%, totaling a maximum of 2.376 million shares [18] - Wanyi Technology reported a net profit of 25.76 million yuan for the first three quarters, turning a profit from a loss [20] - Zhongtai Chemical reported a net loss of 179 million yuan in the first three quarters, with revenue of 21.25 billion yuan, a 5.55% decrease [21] Group 6 - Tend Technology reported a 9.8% increase in net profit for the first three quarters, with revenue of 1.54 billion yuan, a 15.07% increase [22] - Potential Hengxin reported a net loss of 18.19 million yuan in the first three quarters, with revenue of 427 million yuan, an 18.26% increase [27] - Lichen Industrial reported a 90.85% increase in net profit for the third quarter, with revenue of 3.48 billion yuan, a 35.09% increase [29] Group 7 - Saiseng Pharmaceutical reported a 152.81% increase in net profit for the first three quarters, with revenue of 309 million yuan, a 4.41% decrease [31]

Core Insights - The company reported a revenue of 309 million yuan for the first three quarters of 2025, representing a year-on-year decline of 4.41% [1] - The net profit attributable to shareholders increased to 52 million yuan, showing a significant year-on-year growth of 152.81% [1] - Basic earnings per share reached 0.11 yuan, reflecting a year-on-year increase of 155% [1]

Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) reported a year-on-year increase in operating revenue for Q3 2025, but a significant decline in net profit attributable to shareholders [1] Financial Performance - Operating revenue for Q3 2025 reached 112 million yuan, representing a year-on-year increase of 3.50% [1] - Net profit attributable to shareholders was 4.0733 million yuan, showing a year-on-year decrease of 41.41% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -12.8664 million yuan [1]

证券日报网讯 10月23日晚间，赛升药业发布公告称，公司于2025年10月22日召开第五届董事会第十次 会议及第五届监事会第十次会议，审议通过了《关于2025年前三季度全资子公司计提资产减值损失的议 案》。 （文章来源：证券日报） ...

Core Viewpoint - Beijing Saiseng Pharmaceutical Co., Ltd. announced the approval of amendments to its Articles of Association and related governance systems to enhance compliance and governance structure, ensuring alignment with regulatory requirements [1][2][3] Group 1: Articles of Association Revision - The revision of the Articles of Association is based on various laws and regulations, including the Company Law and Securities Law of the People's Republic of China, aimed at optimizing systems and ensuring effective alignment with the latest regulatory frameworks [2] - The proposed amendments will be submitted for approval at the company's second extraordinary general meeting of shareholders in 2025, with management authorized to handle subsequent registration matters [2] Group 2: Governance System Improvement - In addition to revising the Articles of Association, the company is also updating its governance-related systems to enhance operational standards and governance structure [3] - The revisions and new systems are intended to strengthen internal governance and provide a solid foundation for sustainable development, responding to regulatory requirements and improving decision-making efficiency and risk management capabilities [3]

Core Insights - The company reported a revenue of 112 million yuan for Q3 2025, representing a year-on-year increase of 3.50% [1] - The net profit attributable to shareholders decreased by 41.41% to 4.0733 million yuan in Q3 2025 [1] - Basic earnings per share for Q3 2025 stood at 0.01 yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 309 million yuan, which is a year-on-year decline of 4.41% [1] - The net profit attributable to shareholders for the first three quarters increased significantly by 152.81% to 51.8596 million yuan [1] - Basic earnings per share for the first three quarters were reported at 0.11 yuan [1]

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical held its 10th meeting of the 5th Board of Directors on October 22, 2025, where the proposal for the "2025 Q3 Report" was approved [1] - For the year 2024, the revenue composition of Sai Sheng Pharmaceutical is 99.63% from the pharmaceutical manufacturing industry and 0.37% from other businesses [1] - As of the time of reporting, the market capitalization of Sai Sheng Pharmaceutical is 5.8 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - There is a discussion on the hot secondary market for biopharmaceuticals, while the primary market is facing challenges in fundraising [1]

Company Performance - Sai Sheng Pharmaceutical reported a revenue of approximately 309 million yuan for the first three quarters of 2025, a year-on-year decrease of 4.41% [1] - The net profit attributable to shareholders was approximately 51.86 million yuan, reflecting a year-on-year increase of 152.81% [1] - Basic earnings per share increased to 0.11 yuan, marking a year-on-year growth of 155% [1] Market Context - As of the report date, Sai Sheng Pharmaceutical has a market capitalization of 5.8 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion US dollars this year [2] - The secondary market for biopharmaceuticals is experiencing a surge, while the primary market is facing challenges in fundraising [2]

北京赛升药业股份有限公司对外担保管理制度 北京赛升药业股份有限公司 对外担保管理制度 第一章 总则 第一条 为了保护投资者的合法权益，规范北京赛升药业股份有限公司（以 下简称"公司"）的对外担保行为，有效防范公司对外担保风险，确保公司资产 安全，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国民法典》《深圳证券交易所创业板股票上市规则》（以下简称"《创业 板上市规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》等法律、法规、规范性文件以及《北京赛升药业股份有限公司章 程》(以下简称"《公司章程》")的有关规定，结合公司的实际情况，特制订本 制度。 第七条 公司为他人提供担保，应当采取反担保等必要的措施防范风险，反 担保应具有可执行力，反担保的提供方应具备实际承担能力。 第八条 公司独立董事应在年度报告中，对公司累计和当期对外担保情况做 出专项说明。 第二章 对外担保对象的审查 第九条 公司可以为具有独立法人资格并具有以下条件之一的单位提供担 1 北京赛升药业股份有限公司对外担 ...